Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward

References

• Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994;18:501–505. doi:10.1093/clinids/18.4.5018038304
   PubMed Web of Science ®Google Scholar
• Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J. 1997;10:1530–1534. doi:10.1183/09031936.97.100715309230242
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST31573350
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. London, UK: National Institute for Health and Care Excellence; 2019.
   Google Scholar
• Wiersinga WJ, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018;76(1):4–13.29380739
   PubMed Web of Science ®Google Scholar
• Cao B, Huang Y, She DY, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320–1360. doi:10.1111/crj.1267428756639
   PubMed Web of Science ®Google Scholar
• Lee MS, Oh JY, Kang CI, et al. Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother. 2018;50(2):160–198. doi:10.3947/ic.2018.50.2.16029968985
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 1997;336(4):243–250. doi:10.1056/NEJM1997012333604028995086
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382. doi:10.1136/thorax.58.5.37712728155
   PubMed Web of Science ®Google Scholar
• Han X, Zhou F, Li H, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis. 2018;18(1):192. doi:10.1186/s12879-018-3098-529699493
   PubMed Web of Science ®Google Scholar
• Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-acquired Pneumonia Organization International cohort study results. Arch Intern Med. 2009;169(16):1515–1524. doi:10.1001/archinternmed.2009.26519752410
   PubMedGoogle Scholar
• Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med. 2006;119(10):865–871. doi:10.1016/j.amjmed.2006.02.01417000218
   PubMed Web of Science ®Google Scholar
• Egger ME, Myers JA, Arnold FW, Pass LA, Ramirez JA, Brock GN. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Acquired Pneumonia. BMC Med Inform DecisMak. 2016;16:34. doi:10.1186/s12911-016-0270-y
   PubMed Web of Science ®Google Scholar
• Han X, Liu X, Chen L, et al. CAP-China network. Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. BMC Infect Dis. 2020;20(1):668. doi:10.1186/s12879-020-05362-332919458
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA. 2000;283(6):749–755. doi:10.1001/jama.283.6.74910683053
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study. Clin Drug Investing. 2012;32:569–576. doi:10.1007/BF3261911
   Web of Science ®Google Scholar
• Lin TY, Lin SM, Chen HC, et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J. 2007;30:321–332.17939262
   PubMedGoogle Scholar
• Portier H, Brambilla C, Garre M, Paganin F, Poubeau P, Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis. 2005;24:367–376. doi:10.1007/s10096-005-1347-115944847
   PubMed Web of Science ®Google Scholar
• Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–1323. doi:10.1056/NEJMoa140633025830421
   PubMed Web of Science ®Google Scholar
• Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with b-lactams for adults with community acquired pneumonia: systematic review and meta-analysis. Int J Antimicrob Agents. 2015;46:242–248. doi:10.1016/j.ijantimicag.2015.04.01026092096
   PubMed Web of Science ®Google Scholar
• Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA. 2016;315:593–602. doi:10.1001/jama.2016.011526864413
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103(2):309–316. doi:10.1016/j.rmed.2008.08.00618804355
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013;144:999–1007. doi:10.1378/chest.13-006223670047
   PubMed Web of Science ®Google Scholar
• Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother. 2010;8:47–62. doi:10.1016/j.amjopharm.2010.01.00320226392
   PubMed Web of Science ®Google Scholar
• Ito A, Ishida T, Tachibana H, Tokumasu H, Yamazaki A, Washio Y. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis. Sci Rep. 2019;9(1):18406. doi:10.1038/s41598-019-54922-431804572
   PubMed Web of Science ®Google Scholar
• Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs. β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894–1901. doi:10.1001/jamainternmed.2014.488725286173
   PubMed Web of Science ®Google Scholar
• Horita N, Otsuka T, Haranaga S, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology. 2016;21(7):1193–1200. doi:10.1111/resp.1283527338144
   PubMed Web of Science ®Google Scholar
• Liu S, Tong X, Ma Y, et al. Respiratory fluoroquinolones monotherapy vs. beta-lactams with or without macrolides for hospitalized community-acquired pneumonia patients: a meta-analysis. Front Pharmacol. 2019;10:489. doi:10.3389/fphar.2019.0048931139081
   PubMed Web of Science ®Google Scholar
• Frei CR, Burgess DS. Cost-effectiveness of four antimicrobial regimens in patients admitted to the medical floor with class IV or V community-acquired pneumonia. Value Health. 2004;7(3):355. doi:10.1016/S1098-3015(10)62484-9
   Web of Science ®Google Scholar
• Van Werkhoven CH, Postma DF, Mangen MJ, Oosterheert JJ, Bonten MJ. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. BMC Infect Dis. 2017;17(1):52. doi:10.1186/s12879-016-2179-628068956
   PubMed Web of Science ®Google Scholar